REG - Nuformix PLC - NXP002 Update

NuformixAnnouncement

27/06/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220627:nRSa2044Qa&default-theme=true

RNS Number : 2044Q  Nuformix PLC  27 June 2022

27 June 2022

 

Nuformix plc

 

("Nuformix" or the "Company" or the "Group")

 

NXP002 Update

 

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, is pleased to
provide an update in relation to the Company's NXP002 asset, a new form of
tranilast and a potential novel inhaled treatment for Idiopathic Pulmonary
Fibrosis ("IPF").

 

The Company has previously generated positive data on NXP002, demonstrating
that:

 

-      NXP002 can be formulated in a simple and stable solution suitable
for inhaled delivery via nebulisation;

-      NXP002 formulations for nebulisation can be efficiently delivered
to the lung; and

-   NXP002 can dose-dependently regulate the production of mediators
relevant to lung fibrosis and inflammation following a lipopolysaccharide
("LPS") challenge.

However, as announced on 30 May 2022, no conclusions could be drawn from an
additional study undertaken to investigate the duration of action of NXP002
formulations.

The Company has now initiated further studies as it continues to generate a
robust pre-clinical data package to support the progression of NXP002, both in
terms of product development and business development discussions. These
studies will directly address issues faced in the duration of action studies.
Firstly, the Company will investigate a new formulation of NXP002 for
inhalation, delivered using an alternative method designed to ensure
consistent and controlled exposure is achieved. Secondly, the Company will
explore a new range of doses to best optimise efficacy of treatment.

The eventual aim of the studies is to confirm the formulation's positive
pharmacological profile towards the treatment of lung fibrosis and
inflammation via inhalation and to assess its duration of action. The studies
will begin in August 2022 with results generated throughout H2 2022 as
development milestones are achieved. Data from these inhalation studies will
add to the Company's current compelling pre-clinical dataset, to best support
the development of NXP002 as a treatment for IPF and potentially other poorly
treated fibrosing interstitial lung diseases. Further updates will be
announced in due course, as appropriate.

Commenting, Dr Julian Gilbert, Non-executive Director of Nuformix, said:
"NXP002 is our lead programme and after the frustrations of the study
undertaken earlier this year from which no conclusions could be drawn, I am
pleased that we are back on track to investigate the product opportunity
further. The planned programme of studies is intended to ensure we have a
robust pre-clinical data package for NXP002 to support the further progression
of this asset. I look forward to providing further updates in due course as we
progress."

 

Enquiries:

 

 Nuformix plc
 Dr Julian Gilbert, Non-executive Director         Via IFC Advisory

 Maddy Kennedy, Non-executive Director

 Stanford Capital Partners Limited
 Tom Price / Patrick Claridge (Corporate Finance)  +44 (0) 20 3650 3650
 John Howes (Corporate Broking)                    +44 (0) 20 3650 3652

 IFC Advisory Limited
 Tim Metcalfe                                      +44 (0) 20 3934 6630

 Zach Cohen                                        nuformix@investor-focus.co.uk

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities. Nuformix has a pipeline of preclinical assets with potential
for significant value and early licensing opportunities.

 

About Fibrosis

 

Fibrotic disease is typically associated with high patient mortality,
increasing prevalence and a lack of safe and effective treatments. Whilst
fibrosis treatments are in their infancy the emerging lung fibrosis market
demonstrates their blockbuster potential. Idiopathic Pulmonary Fibrosis is
classified as a rare disease and presents a global commercial market that is
forecast to grow to US$8.8bn by 2027. Sales of standard-of-care therapies OFEV
and Esbriet achieved US$2.5bn and US$1bn respectively in 2021.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDZQLFLLQLLBBZ